KRRO

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 2026 Jefferies Global Healthcare Conference being held in New York, NY on June 2nd- 4th, 2026. Dr. Aiyar's presentation will take place on Thursday, June 4, 2026, at 4:20 pm ET. About Korro Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a ne

8-K - Korro Bio, Inc. (0001703647) (Filer)

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungsDemonstrated >90% editing of SERPINA1 transcript in vivo translating into ~90% repaired functional alpha-1 antitrypsin (AAT) protein in plasma in a mouse model of AATDDemonstrated a near elimination of active Z-protein production while showing progressive clearance of pre-existing aggregates in a mouse model of AATDPre-clinical data highlighted the possibility of repeat dose therapy to achieve the functional equivalent of a DNA modification without altering the genome CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Korro

Citigroup initiated coverage of Korro Bio with a rating of Buy and set a new price target of $21.00

SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)

CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 3,000 shares of Korro's common stock at an exercise price of $11.20 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, May 13, 2026. The option has a ten-year term and vests over four years, with 2

424B3 - Korro Bio, Inc. (0001703647) (Filer)

10-Q - Korro Bio, Inc. (0001703647) (Filer)

8-K - Korro Bio, Inc. (0001703647) (Filer)

Hosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); regulatory filing for KRRO-121 expected in the second half of 2026Advanced early-stage research and development programs highlighted by a GalNac-conjugated oligonucleotide for alpha-1 antitrypsin deficiency (AATD); on track to announce development candidate in second quarter of 2026Executed oversubscribed $85 million private placement to support the achievement of value inflection points for multiple RNA editing clinical programs and extend cash runway into the second half of

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Chief Executive Officer and President, Jeffrey Cerio, SVP and General Counsel, Todd Chappell, Chief Operating Officer, and Loïc Vincent, Chief Scientific Officer, will participate in the following investor conferences: HCW 4th Annual BioConnect Nasdaq Investor ConferenceFormat: Fireside chat moderated by Mitchell Kapoor, Director and Senior Analyst, Biotechnology Equity Research, H.

American Society of Gene and Cell Therapy 29th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference3rd International Conference on Ureagenesis Defects and Allied ConditionsEuropean Association for the Study of the Liver (EASL) Congress 2026     CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO),  a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced oral and poster presentations highlighting data from its oligonucleotide delivery based RNA editing technology (OPERA®) will take place at the following scientific confere

DEFA14A - Korro Bio, Inc. (0001703647) (Filer)

DEF 14A - Korro Bio, Inc. (0001703647) (Filer)

CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 15,000 shares of Korro's common stock at an exercise price of $13.46 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, April 8, 2026. The option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of

4 - Korro Bio, Inc. (0001703647) (Issuer)

3 - Korro Bio, Inc. (0001703647) (Issuer)

SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)

EFFECT - Korro Bio, Inc. (0001703647) (Filer)

424B5 - Korro Bio, Inc. (0001703647) (Filer)

S-3 - Korro Bio, Inc. (0001703647) (Filer)

Raymond James upgraded Korro Bio from Mkt Perform to Outperform and set a new price target of $23.00